J&J posts new Phase 3 prostate cancer trial for JNJ-101556143; updates nine other registry records

Johnson & Johnson and its Janssen and Medos units updated ten ClinicalTrials.gov records this week, led by a newly posted Phase 3 prostate cancer trial.

• JNJ-101556143 (prostate cancer, Phase 3): Janssen Research & Development posted NCT07906717 on October 30, 2026, now recruiting. The study will evaluate how well JNJ-101556143 plus Best Supportive Care improves overall survival compared with placebo plus BSC in participants with metastatic androgen pathway modulation-resistant prostate cancer.¹ Enrollment is estimated at 400 participants.¹
• Icotrokinra, ulcerative colitis (Phase 3): NCT07196748 ("ICONIC-UC") is listed as active not recruiting. The protocol evaluates the efficacy, safety and tolerability of oral icotrokinra as induction and maintenance therapy in adult and adolescent participants with moderately to severely active ulcerative colitis.² Enrollment stands at 896 participants.²
• Icotrokinra, psoriatic arthritis (Phase 3): NCT06807424 ("ICONIC-PsA 2") is also active not recruiting. The study compares icotrokinra to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis.³ Enrollment is 813 participants.³
• JNJ-95597528 (asthma, Phase 2b): NCT07746687 ("READY-BREATHE") remains recruiting. The trial assesses how well JNJ-95597528 works compared to placebo in adults with inadequately controlled moderate to severe asthma.⁴ Estimated enrollment is 440 participants.⁴
• JNJ-88545223 (psoriatic arthritis, Phase 2b): NCT07321873 ("VELOTA") is active not recruiting. The study evaluates how well JNJ-88545223 works compared with placebo in adults with active PsA, aiming to see whether the drug can reduce joint and skin signs and symptoms.⁵ Enrollment is 157 participants.⁵
• JNJ-89853413 (relapsed/refractory AML or MDS, Phase 1): NCT06618001 is now completed. The dose-escalation study assessed safety, tolerability and recommended Phase 2 dose in participants with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic neoplasms.⁶ Actual enrollment was 64 participants.⁶
• ENTERPRISE 2 device (intracranial aneurysms, observational): NCT04289480 ("EMPOWER") is completed. The registry evaluated safety and effectiveness of the ENTERPRISE 2 vascular reconstruction device and delivery system to facilitate endovascular coil embolization of intracranial aneurysms.⁷ The lead sponsor is Medos International SARL, with Johnson & Johnson Medical (Shanghai) Ltd. as collaborator.
• Nipocalimab pregnancy outcomes study: NCT07915232 ("PETUNIA"), sponsored by Janssen Research & Development, was first posted November 4, 2026 and is not yet recruiting. It will track pregnancy complications, neonatal and infant health issues, serious infections, and major non-chromosomal birth defects among participants who took nipocalimab before or during pregnancy.⁸ Estimated enrollment is 162 participants.⁸
• Varipulse catheter, paroxysmal atrial fibrillation (observational): NCT07511166 ("GreatPFA"), sponsored by Johnson & Johnson Medical (Shanghai) Ltd., is recruiting. The study assesses how well the Varipulse ablation catheter performs over the long term under different types of anesthesia in participants with symptomatic paroxysmal atrial fibrillation.⁹ Estimated enrollment is 300 participants.⁹
• Real-life standard of care in relapsed/refractory multiple myeloma (observational): NCT05160584 ("MoMMent"), sponsored by Janssen Pharmaceutica N.V., is active not recruiting. The study assesses effectiveness, safety and patient-reported outcomes of standard antimyeloma treatments over a 24-month period in previously treated relapsed and/or refractory multiple myeloma.¹⁰ Actual enrollment is 256 participants.¹⁰